Dexcel Pharma Technologies Ltd. - Oct 1, 2021 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
10%+ Owner
Signature
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
Stock symbol
ROIV
Transactions as of
Oct 1, 2021
Transactions value $
$0
Form type
3
Date filed
10/1/2021, 05:02 PM
Previous filing
Jun 3, 2021
Next filing
Apr 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ROIV Common Shares 98.8M Oct 1, 2021 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 643,845 common shares. Dexxon Holdings Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.